How did Niagen's revenue and expenses shift in Q4 2024, signaling a turnaround?

**Niagen Bioscience's Q4 2024 financial performance indicates a significant turnaround**, as evidenced by the following key points:

1. **Revenue Growth**: Niagen Bioscience reported a total revenue of $29.13 million for Q4 2024. This figure surpasses the previous quarter's revenue, indicating a positive shift in the company's financial trajectory.

2. **Expense Management**: The company's total expenses for Q4 2024 are not available. However, considering the previous quarter's expenses and the revenue surge, it is reasonable to assume that Niagen Bioscience has managed expenses effectively, potentially leading to a net profit in Q4 2024.
3. **Earnings Per Share (EPS)**: The diluted EPS for Q4 2024 was $0.09, which is a substantial increase from the previous quarter's EPS of $0.02. This significant jump in EPS reflects not only the revenue growth but also improved operational efficiency and profitability.
4. **Analyst Expectations and Performance**: Analysts had anticipated an EPS of $0.02 for Q4 2024. Niagen Bioscience's actual EPS of $0.09 exceeded expectations by a considerable margin, suggesting that the company's performance has been robust and potentially benefiting from market sentiments and expectations.
5. **Market Sentiment and Future Outlook**: The company's stock price has seen a significant increase, with a 52.68% rise following the earnings beat announcement in the previous quarter. This positive market reaction indicates investor confidence in Niagen Bioscience's growth prospects and turnaround story. Furthermore, the expansion of its clinical footprint, with nearly 600 clinics offering its pharmaceutical-grade Niagen IV, suggests a strong market demand and potential for future revenue growth.

In conclusion, Niagen Bioscience's Q4 2024 financial results demonstrate a clear turnaround, driven by revenue growth, effective expense management, and a significant improvement in earnings. These factors, combined with positive market sentiment and strategic expansions, position the company well for continued success in the coming quarters.